Themis Medicare Limited Stock NSE India S.E.

Equities

THEMISMED

INE083B01024

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:55 2024-06-27 EDT 5-day change 1st Jan Change
209.8 INR -2.23% Intraday chart for Themis Medicare Limited -5.32% -1.84%

Financials

Sales 2023 3.54B 42.47M 58.18M Sales 2024 3.82B 45.76M 62.68M Capitalization 20.16B 242M 331M
Net income 2023 569M 6.82M 9.34M Net income 2024 435M 5.21M 7.14M EV / Sales 2023 3.25 x
Net Debt 2023 798M 9.57M 13.11M Net Debt 2024 859M 10.29M 14.1M EV / Sales 2024 5.5 x
P/E ratio 2023
18.9 x
P/E ratio 2024
46.4 x
Employees 1,509
Yield 2023
0.43%
Yield 2024
0.23%
Free-Float 21.12%
More Fundamentals * Assessed data
Dynamic Chart
Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or after July 22, 2024 CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Themis Medicare Limited Launches REMITHEM CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023 CI
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023 CI
Themis Medicare Limited Announces Board Resignations CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection MT
More news
1 day-2.23%
1 week-5.32%
Current month+3.46%
1 month-1.64%
3 months-5.58%
6 months-4.24%
Current year-1.84%
More quotes
1 week
208.21
Extreme 208.21
225.40
1 month
180.55
Extreme 180.55
226.93
Current year
180.55
Extreme 180.55
263.85
1 year
132.61
Extreme 132.605
263.85
3 years
65.67
Extreme 65.665
263.85
5 years
13.83
Extreme 13.83
263.85
10 years
9.49
Extreme 9.49
263.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 04-06-28
Director of Finance/CFO - 16-09-30
Chairman 75 72-12-31
Members of the board TitleAgeSince
Chief Executive Officer 49 04-06-28
Chairman 75 72-12-31
Director/Board Member 70 76-12-31
More insiders
Date Price Change Volume
24-06-27 209.8 -2.23% 37,239
24-06-26 214.6 -2.14% 32,290
24-06-25 219.2 +1.72% 54,901
24-06-24 215.5 -1.87% 48,239
24-06-21 219.6 -0.82% 35,396

Delayed Quote NSE India S.E., June 27, 2024 at 07:43 am

More quotes
Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.
More about the company